OSCR

Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8<sup>+</sup> T cell responses and promoting tertiary lymphoid structure formation.

Overview

Authors: Kazutaka Hosoya1, Hiroaki Ozasa1, Takahiro Tsuji2, Masahiro Oi1, Yusuke Shima1, Keiichiro Suminaga1, Kentaro Hashimoto1, Hiroshi Yoshida1, Tomoko Funazo1, Hitomi Ajimizu1, Takashi Nomizo1, Hironori Yoshida1, Hiroyuki Katsuragawa3, Kentaro Tsuji3, Noritaka Sano4, Shigeki Takada4, Yohei Mineharu4,5, Shigeto Nishikawa6, Toshi Menju6, Akihiko Yoshizawa7, Yoshiki Arakawa4, Hiroaki Wake2,8,9, Toyohiro Hirai1
  1. Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
  2. Department of Anatomy and Molecular Cell Biology, Nagoya University Graduate School of Medicine, Nagoya, Japan
  3. Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan
  4. Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
  5. Department of Digital Transformation in Healthcare and Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
  6. Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
  7. Department of Diagnostic Pathology, Nara Medical University, Kashihara, Japan
  8. Division of Multicellular Circuit Dynamics, National Institute for Physiological Sciences, Okazaki, Japan
  9. Department of Physiological Sciences, Graduate University for Advanced Studies, SOKENDAI, Hayama, Japan
Journal: Nature communications, volume 17, issue 1, article 5681
Dates: received 17 September 2025; accepted 16 June 2026; published online 7 July 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.1038/s41467-026-74782-7 · PMID 42414284 · PMCID PMC13342341 · OpenAlex W7167605159
Open access: gold, a free copy (OpenAlex)
Categories: human (organism), mouse (organism), other condition (population), cellular / molecular (subfield)
Methods: Statistics, Smoothing, state filtering, decompositions, fMRI & imaging
Keywords: Cancer microenvironment, Non-small-cell lung cancer, Cancer immunotherapy
MeSH: Brain Neoplasms*, Carcinoma, Non-Small-Cell Lung*, CD8-Positive T-Lymphocytes*, CTLA-4 Antigen*, Immune Checkpoint Inhibitors*, Lung Neoplasms*, Programmed Cell Death 1 Receptor*, Tertiary Lymphoid Structures*, Animals, Cell Line, Tumor, Female, Humans, Ipilimumab, Mice, Mice, Inbred C57BL, T-Lymphocytes, Cytotoxic, Tumor Microenvironment (* major topic)
Topic: Cancer Immunotherapy and Biomarkers (Oncology, Medicine), according to OpenAlex
Funding: Nippon Boehringer Ingelheim Co., Ltd. JST SPRING (grant number JPMJSP2110) JSPS KAKENHI
Citations: cited by 1 paper (Europe PMC); 53 references in the paper

Abstract

Brain metastases (BrMs) in non-small cell lung cancer (NSCLC) respond poorly to anti-PD-1 monotherapy, but the underlying immune resistance remains incompletely defined. Here we integrate clinical outcome analyses, paired human tissue profiling and syngeneic mouse models to characterize the BrM immune microenvironment. Clinical analyses suggest improved intracranial disease control with nivolumab plus ipilimumab compared with nivolumab alone. Paired human specimens show that BrMs contain fewer cytotoxic T lymphocytes (CTLs) and tertiary lymphoid structures (TLSs) than primary tumors, defining an immune-excluded phenotype. A syngeneic BrM model recapitulates this phenotype and resists anti-PD-1 monotherapy, whereas combined anti-PD-1 and anti-CTLA-4 blockade suppresses tumor growth and prolongs survival. Single-cell RNA sequencing, flow cytometry and immunofluorescence show increased CTL infiltration and effector function after combination therapy. CD8+ T cell depletion abrogates therapeutic benefit, and combination therapy expands T follicular helper-like cells and induces TLS-like structures. These findings manifest increased adaptive immune response of dual checkpoint blockade in NSCLC BrMs.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Code availability

No custom code was developed in this study. All analyses were performed using publicly available software and packages described in the Methods section.

Reproduced under the paper's license (CC BY), from the paper cited above.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data Availability Statement

Source data are provided with this paper. Raw single-cell RNA sequencing data have been deposited in the DDBJ database [https://ddbj.nig.ac.jp/search/entry/gea/E-GEAD-1219], accession no: E-GEAD-1219. Raw FASTQ files are available from the DDBJ Sequence Read Archive (DRA) under accession numbers DRR909906–DRR909909, linked to GEA accession E-GEAD-1219. The raw microarray datasets used in this study are available from the Gene Expression Omnibus under accession codes GSE161116 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE161116) and GSE248830 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248830). All other data generated in this study are provided in the Supplementary information, Supplementary data and Source data files. Source data are provided with this paper.

No custom code was developed in this study. All analyses were performed using publicly available software and packages described in the Methods section.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 23 authors, 3 keywords, 17 MeSH terms, 1 funder, 53 references.

Cite

This paper

Hosoya, K., Ozasa, H., Tsuji, T., Oi, M., Shima, Y., Suminaga, K., Hashimoto, K., Yoshida, H., Funazo, T., Ajimizu, H., Nomizo, T., Yoshida, H., Katsuragawa, H., Tsuji, K., Sano, N., Takada, S., Mineharu, Y., Nishikawa, S., Menju, T., . . . Hirai, T. (2026). Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8<sup>+</sup> T cell responses and promoting tertiary lymphoid structure formation. Nature communications, 17(1), 5681. https://doi.org/10.1038/s41467-026-74782-7

BibTeX

@article{hosoya2026anti,
author = {Hosoya, Kazutaka and Ozasa, Hiroaki and Tsuji, Takahiro and Oi, Masahiro and Shima, Yusuke and Suminaga, Keiichiro and Hashimoto, Kentaro and Yoshida, Hiroshi and Funazo, Tomoko and Ajimizu, Hitomi and Nomizo, Takashi and Yoshida, Hironori and Katsuragawa, Hiroyuki and Tsuji, Kentaro and Sano, Noritaka and Takada, Shigeki and Mineharu, Yohei and Nishikawa, Shigeto and Menju, Toshi and Yoshizawa, Akihiko and Arakawa, Yoshiki and Wake, Hiroaki and Hirai, Toyohiro},
title = {{Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8\<sup\>+\</sup\> T cell responses and promoting tertiary lymphoid structure formation}},
journal = {Nature communications},
year = {2026},
month = jul,
volume = {17},
number = {1},
pages = {5681},
publisher = {Nature Publishing Group},
issn = {2041-1723},
doi = {10.1038/s41467-026-74782-7},
url = {https://doi.org/10.1038/s41467-026-74782-7},
pmid = {42414284},
pmcid = {PMC13342341}
}

RIS

TY - JOUR
AU - Hosoya, Kazutaka
AU - Ozasa, Hiroaki
AU - Tsuji, Takahiro
AU - Oi, Masahiro
AU - Shima, Yusuke
AU - Suminaga, Keiichiro
AU - Hashimoto, Kentaro
AU - Yoshida, Hiroshi
AU - Funazo, Tomoko
AU - Ajimizu, Hitomi
AU - Nomizo, Takashi
AU - Yoshida, Hironori
AU - Katsuragawa, Hiroyuki
AU - Tsuji, Kentaro
AU - Sano, Noritaka
AU - Takada, Shigeki
AU - Mineharu, Yohei
AU - Nishikawa, Shigeto
AU - Menju, Toshi
AU - Yoshizawa, Akihiko
AU - Arakawa, Yoshiki
AU - Wake, Hiroaki
AU - Hirai, Toyohiro
TI - Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8<sup>+</sup> T cell responses and promoting tertiary lymphoid structure formation
T2 - Nature communications
J2 - Nat Commun
PY - 2026
DA - 2026/07/07
VL - 17
IS - 1
SP - 5681
SN - 2041-1723
PB - Nature Publishing Group
DO - 10.1038/s41467-026-74782-7
UR - https://doi.org/10.1038/s41467-026-74782-7
LA - en
ER -

CSL-JSON

{
"id": "10.1038/s41467-026-74782-7",
"type": "article-journal",
"title": "Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8<sup>+</sup> T cell responses and promoting tertiary lymphoid structure formation",
"container-title": "Nature communications",
"author": [
{
"family": "Hosoya",
"given": "Kazutaka"
},
{
"family": "Ozasa",
"given": "Hiroaki"
},
{
"family": "Tsuji",
"given": "Takahiro"
},
{
"family": "Oi",
"given": "Masahiro"
},
{
"family": "Shima",
"given": "Yusuke"
},
{
"family": "Suminaga",
"given": "Keiichiro"
},
{
"family": "Hashimoto",
"given": "Kentaro"
},
{
"family": "Yoshida",
"given": "Hiroshi"
},
{
"family": "Funazo",
"given": "Tomoko"
},
{
"family": "Ajimizu",
"given": "Hitomi"
},
{
"family": "Nomizo",
"given": "Takashi"
},
{
"family": "Yoshida",
"given": "Hironori"
},
{
"family": "Katsuragawa",
"given": "Hiroyuki"
},
{
"family": "Tsuji",
"given": "Kentaro"
},
{
"family": "Sano",
"given": "Noritaka"
},
{
"family": "Takada",
"given": "Shigeki"
},
{
"family": "Mineharu",
"given": "Yohei"
},
{
"family": "Nishikawa",
"given": "Shigeto"
},
{
"family": "Menju",
"given": "Toshi"
},
{
"family": "Yoshizawa",
"given": "Akihiko"
},
{
"family": "Arakawa",
"given": "Yoshiki"
},
{
"family": "Wake",
"given": "Hiroaki"
},
{
"family": "Hirai",
"given": "Toyohiro"
}
],
"container-title-short": "Nat Commun",
"volume": "17",
"issue": "1",
"page": "5681",
"DOI": "10.1038/s41467-026-74782-7",
"PMID": "42414284",
"PMCID": "PMC13342341",
"ISSN": "2041-1723",
"publisher": "Nature Publishing Group",
"URL": "https://doi.org/10.1038/s41467-026-74782-7",
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
7
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1371/journal.pone.0303002 [code]
Postoperative Karnofsky performance status prediction in patients with IDH wild-type glioblastoma: A multimodal approach integrating clinical and deep imaging features.
Journal: PloS one
In common: other condition, 2 authors
[2] doi:10.1038/s43018-023-00566-3
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation.
Journal: Nature cancer
In common: other condition, cellular / molecular, 5 references
[3] doi:10.1158/2159-8290.cd-24-0134
TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells.
Journal: Cancer discovery
In common: other condition, mouse, cellular / molecular, 5 references
[4] doi:10.1038/s41467-026-68748-y
A proteogenomic atlas of 1032 brain metastases identifies molecular subtypes, immune landscapes, and therapeutic vulnerabilities.
Journal: Nature communications
In common: other condition, cellular / molecular, 4 references
[5] doi:10.1136/jitc-2024-009522
Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases.
Journal: Journal for immunotherapy of cancer
In common: other condition, mouse, 4 references
[6] doi:10.3390/ijms27083598
Decoding Prognostic Signatures in Brain Metastatic Non-Small-Cell Lung Cancer via Integrated Multi-Omics and Network Analysis.
Journal: International journal of molecular sciences
In common: NCBI GEO GSE161116, other condition, 1 reference
[7] doi:10.1093/oncolo/oyac064
Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases.
Journal: The oncologist
In common: other condition, 4 references
[8] doi:10.1038/s41586-022-05680-3 [code]
Single-cell spatial immune landscapes of primary and metastatic brain tumours.
Journal: Nature
In common: other condition, 4 references
[9] doi:10.1038/s42003-022-03917-5
A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice.
Journal: Communications biology
In common: other condition, mouse, cellular / molecular, author Yoshiki Arakawa
[10] doi:10.1038/s41586-024-07493-y [code]
Single-cell atlas of the human brain vasculature across development, adulthood and disease.
Journal: Nature
In common: other condition, author Shigeki Takada

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.